admitted Thursday that problems with its human blood substitute Hemopure are forcing it to delay filing an approval application with U.S. drug regulators for at least six months. also reported that a ...

Howard Richman better hope there's no such thing as karma. The former BioPure vice president was sentenced last month to three years in prison for faking cancer to avoid an SEC investigation. The ...

With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle ...

BioPure, a leading provider of single-use fluid path components and connectors since 1998, has advanced the manufacturing of BioClamp to bring sustainability benefits to users BioClamp is manufactured ...

> After months of teetering on the brink, Biopure has filed for bankruptcy as it clears a path to selling its assets to OPK Biotech. Biopure had tried unsuccessfully to develop the synthetic blood ...

Biopure bpur is tumbling almost 14 percent to $2.37 after the Cambridge, Mass., developer of blood substitute products named Ronald Reynolds chief financial officer, replacing Francis Murphy, who will ...

Biopure, the disgraced developer of a failed human blood substitute, is attempting a comeback. It’s a biotech resurrection that seems quixotic at best. Delusional might be more accurate, given the ...

BioPure, a subsidiary of Watson-Marlow Fluid Technology Group, debuted its expanded manufacturing facility at Dunsbury Park near Portsmouth in the U.K. BioPure designs and develops bioprocessing fluid ...

said Wednesday that it expects to run out of money in eight weeks, adding that it must raise $19 million to keep operating through October. The announcement is the latest in a series of regulatory and ...

Waterlooville, UK, 12th January 2021 / Sciad Newswire / Based in Waterlooville, Hampshire, BioPure manufactures biotech components that have become the standard in biopharmaceutical development and ...